Objective: To observe the effect of Tangshen prescription combined with beraprost sodium on inflammatory factors and safety of patients with diabetic kidney disease (DKD). Method: The randomized parallel control study was carried on among three groups

which were the traditional Chinese medicine(TCM) group (Tangshen prescription)

the western medicine group (beraprost sodium) and the combined group (combination of the two medicines). Clinical curative effect

symptom score

fasting blood glucose (FBG)

urinary albumin excretion rate (UAER)

and relevant inflammatory factors

such as interleukin (IL)-18

tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β1 were observed before and after the administration. Result: After treatment

all of the indexes in each group were significantly reduced

compared with before treatment. Compared with western medicine group

the level of FBG in TCM group was significantly lower

with statistically significant differences (P < 0.05). The level of IL-18 in western medicine group was lower than that of traditional Chinese medicine group

with statistically significant differences (P < 0.05). Compared with group

the total clinical efficiency of combined group increased

with statistically significant differences (P < 0.05); and it was also increased in combined group

compared with western medicine group

with statistically significant differences (P < 0.01). In improving the deficiency of spleen Qi (soreness and weakness of waist and knees and thirst without desire to drink)

and reducing the levels of FBG

UAER and inflammatory factors

the combined group was superior to both group and western medicine group

with statistically significant differences (P < 0.05). In releasing the deficiency of spleen Qi (fatigue

anorexia and swollen limbs)

combined group was superior to western medicine group

with statistically significant differences (P < 0.05). No serious adverse reaction was found in three groups. Conclusion: Tangshen prescription combined with beraprost sodium could enhance the effect of reducing proteinuria and inflammation

with a better effect in treatment of DKD at the clinical stage.